Protara Therapeutics to Participate in Upcoming Investor Conferences
Protara Therapeutics, Inc. (Nasdaq: TARA) announced its participation in two upcoming investor conferences, including the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference and the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The company will hold fireside chats at these events, with a live webcast available on their website.
01/31/2024 - 07:30 AM
NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences:
Guggenheim Healthcare Talks 6th Annual Biotechnology Conference. A fireside chat will take place on Wednesday, February 7, 2024 at 10:30 am ET in New York. Oppenheimer 34th Annual Healthcare Life Sciences Conference. A fireside chat will take place virtually on Wednesday, February 14, 2024 at 8:40 am ET. A live webcast of the events can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com . The webcasts will be archived for a limited time following the presentations.
About Protara Therapeutics, Inc. Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com .
Company Contact: Justine.OMalley@protaratx.com
Protara Therapeutics will participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 10:30 am ET in New York.
The live webcast of the events can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com.
Protara Therapeutics will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024 at 8:40 am ET.
Yes, the webcasts will be archived for a limited time following the presentations.
TARA Rankings
#4923 Ranked by Stock Gains
TARA Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Pharmaceuticals: Major, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
New York
About TARA
protara therapeutics, inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. the company's lead program is tara-002, an investigational cell therapy for the treatment of lymphatic malformations. it also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. the company was formerly known as artara therapeutics, inc. and changed its name to protara therapeutics, inc. in may 2020. protara therapeutics, inc. is based in new york, new york.
